Investment firm I Love Lund expects a "distinctly positive" financial impact following the acquisition of Swedish-founded Saga Diagnostics by Swiss pharmaceutical giant Roche for $595 million, according to a press release.

I Love Lund holds a stake in Saga Diagnostics after participating in a 2021 funding round. The firm has invested a total of just over $115,000, equivalent to 1.1 million SEK, and currently holds 198,649 Series A preferred shares.

While I Love Lund anticipates a positive outcome from the transaction, it is currently unable to provide specific details regarding the potential size or scope of the proceeds.

"The holding is not currently recorded as one of I Love Lund's most significant positions, yet the expected purchase price could still have a substantial positive impact on our earnings for the year," the company stated.